SCHEMBL19996089

SCHEMBL19996089

ClCc1ncccc1Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.46
PAX8 Q06710 1/20 0.45
KDM4E B2RXH2 1/20 0.42
HTR2A P28223 1/20 0.40
LIMK2 P53671 1/20 0.40
POLB P06746 1/20 0.40
CALM1 P0DP23 1/20 0.39
BCL2 P10415 1/20 0.38
BCL2L1 Q07817 1/20 0.38
HSP90AA1 P07900 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 1/20 0.38
CYP11B1 P15538 1/20 0.37
CYP11B2 P19099 1/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
RAB9A P51151 1/20 0.37
HTT P42858 1/20 0.37
MAOA P21397 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2232473 0.86 MET (0.50) METPAX8KDM4EHTR2ALIMK2
Ammonia Solution, Strong SCHEMBL28590384 0.85 MET (0.49) METPAX8KDM4EHTR2ALIMK2
SCHEMBL30022256 0.85 MET (0.49) METPAX8KDM4EHTR2ALIMK2
SCHEMBL17183942 0.81 MET (0.50) METPAX8KDM4EHTR2ALIMK2
SCHEMBL5102757 0.81 ALDH1A1 (0.50) METPAX8KDM4EHTR2ALIMK2
SCHEMBL360266 0.80 ALDH1A1 (0.40) KDM4EHSP90AA1SMN1; SMN2CYP11B1CYP11B2
SCHEMBL29900533 0.80 ALDH1A1 (0.40) KDM4EHSP90AA1SMN1; SMN2CYP11B1CYP11B2
SCHEMBL29501702 0.79 MET (0.50) METPAX8KDM4EHTR2ALIMK2
SCHEMBL10341448 0.79 MET (0.50) METPAX8KDM4EHTR2ALIMK2
Hydrochloric Acid SCHEMBL1856795 0.78 ALDH1A1 (0.39) KDM4EHSP90AA1SMN1; SMN2CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200040025-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY 2020-02-06 US disclosed
EP-3515447-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE Tufts University (US) 2019-07-31 EP disclosed
WO-2018058148-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE TUFTS UNIVERSITY (US) 2018-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040025-A1 URIDINE NUCLEOSIDE DERIVATIVES, COMPOSITIONS AND METHODS OF USE P2RY6, UPP1, UMPS MET 4849/4885PAX8 3447/4885KDM4E 4732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.